<?xml version="1.0" encoding="UTF-8"?>
<p>Oleuropein was found to display antiproliferative, proapoptotic effects [
 <xref rid="B92-ijms-19-00686" ref-type="bibr">92</xref>], overall anticancer activity [
 <xref rid="B93-ijms-19-00686" ref-type="bibr">93</xref>], and specifically an ability to decrease cancer cell viability [
 <xref rid="B94-ijms-19-00686" ref-type="bibr">94</xref>], as well as induction of cancer cell apoptosis [
 <xref rid="B95-ijms-19-00686" ref-type="bibr">95</xref>,
 <xref rid="B96-ijms-19-00686" ref-type="bibr">96</xref>,
 <xref rid="B97-ijms-19-00686" ref-type="bibr">97</xref>,
 <xref rid="B98-ijms-19-00686" ref-type="bibr">98</xref>]. Oleuropein induces apoptosis in breast cancer cells (MCF-7) via the 
 <italic>p53</italic>-dependent pathway and through the regulation of 
 <italic>Bax</italic> and 
 <italic>Bcl2</italic> genes. Therefore, oleuropein may have a great therapeutic potential for breast cancer treatment [
 <xref rid="B99-ijms-19-00686" ref-type="bibr">99</xref>]. Interestingly, oleuropein has been reported to inhibit aromatase, a cytochrome P450 enzyme, which is an important pharmacological target in breast cancer therapy [
 <xref rid="B100-ijms-19-00686" ref-type="bibr">100</xref>]. Moreover, it increases cancer cell sensitivity to trastuzumab (&gt;1000-fold increase) in SKBR3/Tzb100 cell model of acquired resistance [
 <xref rid="B62-ijms-19-00686" ref-type="bibr">62</xref>]. Studies in animal models have shown that oleuropein administration prevents breast cancer [
 <xref rid="B87-ijms-19-00686" ref-type="bibr">87</xref>], skin cancer [
 <xref rid="B101-ijms-19-00686" ref-type="bibr">101</xref>], and various soft tissue cancers [
 <xref rid="B86-ijms-19-00686" ref-type="bibr">86</xref>]. 
</p>
